Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer

Journal of Pathology

Volumn 189, Issue 4, 1999, Pages 514-520

  Gee, Julia M W ^a   Robertson, John F R ^b   Ellis, Ian O ^b   Nicholson, Robert I ^a   Hurst, Helen C ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

AP 2; Breast tumours; ERBB2; Oestrogen receptor; P21(cip); Transcription factors

Indexed keywords

TRANSCRIPTION FACTOR AP 2;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; STATISTICS, NONPARAMETRIC; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 0032716985     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9     Document Type: Article

References (26)

1. Moser M, Ruschoff J, Buettner R. Comparative analysis of AP-2α and AP-2β gene expression during murine embryogenesis. Dev Dyn 1997; 208: 115-124.
2. Chazaud C, Oulad-Abdelghani M, Bouillet P, Decimo D, Chambon P, Dolle P. AP-2.2, a novel gene related to AP-2 is expressed in the forebrain, limbs and face during mouse embryogenesis. Mech Dev 1996; 54: 83-94.
3. Zhang J, Hagiopian-Donaldson S, Serbedzija G, et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996; 381: 238-241.
4. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ. Transcription factor AP-2 is essential for cranial closure and craniofacial development. Nature 1996; 381: 235-238.
5. Moser M, Psherer A, Roth C, et al. Enhanced apoptotic cell-death of renal epithelial cells in mice lacking transcription factor AP-2β. Genes Dev 1997; 11: 1938-1948.
6. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in ERBB2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A 1995; 92: 744-747.
7. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates ERBB2 expression in mammary carcinoma. Oncogene 1996; 13: 1701-1707.
8. Hynes NE. Stern DF. The biology of erbb-2/neu/her-2 and its role in cancer. Biochim Biophys Acta (Rev Cancer) 1994; 1198: 165-175.
9. McPhearson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP-2 transcription factor family. Proc Natl Acad Sci U S A 1997; 94: 4342-4347.
10. cip1/waf1 expression. Nature Genet 1997; 15: 78-82.
11. Gee JMW, Robertson JFR, Ellis IO, et al. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619-628.
12. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGFR, c-erbB-2 protein expression and Ki67 immunostaining in breast-cancer and hormone sensitivity. Eur J Cancer 1993; 29A: 1018-1023.
13. Knowlden JM, Gee JMW, Seery LT, et al. ErbB3 and ErbB4 expression are a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998; 17: 1949-1957.
14. Gee JMW, Ellis IO, Robertson JFR, et al. Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1995; 64: 269-273.
15. Nicholson RI, McClelland RA, Gee JMW, et al. Transforming growth-factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 1994; 54: 1684-1689.
16. cip expression and endocrine response in breast cancer. J Pathol 1999; 188: 126-132.
17. Nicholson RI, Bouzubar N, Walker KJ, et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 1991; 27: 908-913.
18. Hayward JL, Carbonne PP, Heuson JC, Kumaoka S, Rubens R. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer. Cancer 1977; 39: 1289-1293.
19. British Breast Group. Assessment of response to treatment in advanced breast cancer. Lancet 1974; 2: 38-39.
20. Gilbertson RJ, Perry RH, Kelly PJ, Pearson ADJ, Lunec J. Prognostic significance of Her2 and Her4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-3280.
21. Turner B, Zhang J, Gumbs AA, et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 1998; 58: 5466-5472.
22. Foulkes WD, Ragoussis J, Stamp GWH, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome-6 in human ovarian carcinoma. Br J Cancer 1993; 67: 551-559.
23. Nawroz H, Vanderriet P, Hruban RH, Koch W, Ruppert JM, Sidransky D. Allelotype of head and neck squamous-cell carcinoma. Cancer Res 1994; 54: 1152-1155.
24. Robertson GP, Coleman AB, Lugo TG. Mechanisms of human-melanoma cell-growth and tumor suppression by chromosome-6. Cancer Res 1996; 56: 1635-1641.
25. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologs of two new members of the AP-2 family of transcription factors. Genomics 1996; 35: 262-264.
26. Jean D, Gershenwald JE, Huang SY, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumour-growth and metastasis of human melanoma cells. J Biol Chem 1998; 273: 16 501-16 508.